# US 2016/0355459 A1 · Small Molecule Inhibitors of Dusp6 and Uses Therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355459 A1
- Document ID: US20160355459A1
- Status: Published application
- Kind: A1
- Application number: 15/243,089
- Filed: 2016-08-22
- Published: 2016-12-08
- Earliest claimed: 2009-03-20
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Billy W. Day; Waikok Michael Tsang; Vasiliy N. Korotchenko
- Web page: https://patentgrep.com/patent/US20160355459A1

## CPC

- C07C 225/20: having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- C07C 211/42: with six-membered aromatic rings being part of the condensed ring systems
- C07D 495/04: Ortho-condensed systems
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses.

## Claims

### Claim 1

A compound having the formula:
in which R1 represents one or more independently of H, halo, C1-3 alkyl, C1-3 alkoxyl or —CN; R2 is a a secondary or tertiary amine group; R3 is one or more independently of H, halo, C1-3 alkyl, C1-3 alkoxyl or —CN; and R4 is ═O or —OH, wherein
when both R1 and R3 are H,
R4 is —OH, or
R3 is one or more independently of halo, C1-3 alkyl, C1-3 alkoxyl or —CN, and
when R1 is H and R4 is ═O, R3 is one or more independently of halo, C1-3 alkyl, C1-3 alkoxyl or —CN,
or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 in which R2 is a C4-10 cycloalkylamine.

### Claim 3 (depends on 1)

The compound of claim 1 in which R2 is one of cyclopentylamine and cycloheptylamine.

### Claim 4 (depends on 1)

The compound of claim 1 consisting essentially of a (−) enantiomer of the compound.

### Claim 5 (depends on 1)

The compound of claim 1 having the formula:

### Claim 6 (depends on 1)

The compound of claim 1 in which R4 is ═O.

### Claim 7 (depends on 6)

The compound of claim 6 in which R2 is one of 4-t-Boc-cyclohexylamine, thiamorpholine, piperazine, methyl piperazine, acetyl piperazine, cyclopentylamine, cycloheptylamine and di-C1-4-alkylamine.

### Claim 8 (depends on 1)

The compound of claim 1 in which R4 is —OH.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is 3,4-di-halo.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R1 is 3,4-dichloro.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is one of C4-10 cycloalkylamine, 4-t-Boc-cyclohexylamine, thiamorpholine, piperazine, methyl piperazine, acetyl piperazine, phenylamine, piperidine, morpholine, biotin, and di-C1-4-alkylamine.

### Claim 12 (depends on 1)

A composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable excipient.

### Claim 13

A method of inhibiting dual specificity phosphatase 6 (Dusp6)-induced dephosphorylation of extracellular signal-related kinase (ERK), comprising contacting a cell with a compound having the formula:
in which R1 represents one or more independently of H, halo, C1-3 alkyl, C1-3 alkoxyl or —CN; R2 is a secondary or tertiary amine group; R3 is one or more independently of H, halo, C1-3 alkyl, C1-3 alkoxyl or —CN; and R4 is ═O or —OH, wherein
when both R1 and R3 are H,
R4 is —OH, or
R3 is one or more independently of halo, C1-3 alkyl, C1-3 alkoxyl or —CN, and
when R1 is H and R4 is ═O, R3 is one or more independently of halo, C1-3 alkyl, C1-3 alkoxyl or —CN,
or a pharmaceutically-acceptable salt thereof, in an amount effective to inhibit dephosphorylation of ERK by Dusp6.

### Claim 14 (depends on 13)

The method of claim 13, wherein R3 is halo.

### Claim 15 (depends on 14)

The method of claim 14, where R3 is Br.

### Claim 16 (depends on 13)

The method of claim 13, wherein R2 is a C4-10 cycloalkylamine.

### Claim 17 (depends on 13)

The method of claim 13, wherein R2 is one of cyclopentylamine and cycloheptylamine.

### Claim 18 (depends on 13)

The method of claim 13, wherein R1 is H, R2 is one of cyclopentylamine, cyclohexylamine, and cycloheptylamine, and R3 is Br.

### Claim 19 (depends on 18)

The method of claim 18, wherein R2 is cyclohexylamine.

### Claim 20 (depends on 13)

The method of claim 13, wherein the compound has the structure:
